特恩治疗公司非GAAP每股收益为-0.07美元

2025-11-13 23:06

Turn Therapeutics Inc. press release (TTRX): Q3 Non-GAAP EPS of -$0.07.
Research and Development (R&D) Expenses: Research and development expenses for the three months ended September 30, 2025 were $158,699 compared to $153,282 for the three months ended September 30, 2024.
General and Administrative (G&A) Expenses: General and administrative expenses for the three months ended September 30, 2025 were $1.75 million, an increase of $1.2 million, compared to $0.52 million for the three months ended September 30, 2024. The increase was primarily a result of an increase in legal services, advisory services and other fees related to the Company’s direct listing on Nasdaq.
Other income remained comparable with no material change for the three months ended September 30, 2025 when compared to three months ended September 30, 2024.
As of September 30, 2025, the Company had $3.11 million in cash and cash equivalents.

More on Turn Therapeutics Inc.